CRC Clinical Trials in Seattle, Washington

9 recruitingSeattle, Washington

Showing 19 of 9 trials

Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

Colorectal, CancerOvarian CancerLung Cancer+17 more
A2 Biotherapeutics Inc.474 enrolled12 locationsNCT06051695
Recruiting
Phase 1

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Non-small Cell Lung CancerNSCLCMetastatic Pancreatic Ductal Adenocarcinoma+11 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)665 enrolled17 locationsNCT06917079
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

CRC (Colorectal Cancer)
Incyte Corporation700 enrolled274 locationsNCT07284849
Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Colorectal, CancerPancreatic CancerHead and Neck Squamous Cell Carcinoma (HNSCC)+14 more
A2 Biotherapeutics Inc.200 enrolled16 locationsNCT04981119
Recruiting
Phase 1Phase 2

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

TNBC - Triple-Negative Breast CancerAdvanced Solid TumorsNSCLC+3 more
Tubulis GmbH250 enrolled16 locationsNCT06657222
Recruiting
Phase 1Phase 2

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.754 enrolled21 locationsNCT05379985
Recruiting
Phase 1Phase 2

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Colorectal, CancerPancreatic Ductal AdenocarcinomaMetastatic Pancreatic Ductal Adenocarcinoma+3 more
Revolution Medicines, Inc.1,130 enrolled32 locationsNCT06445062
Recruiting
Phase 2

Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)

Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Stingray Therapeutics70 enrolled6 locationsNCT06589440
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

Triple-Negative Breast CancerColorectal, CancerLung Cancer+14 more
A2 Biotherapeutics Inc.240 enrolled10 locationsNCT06682793